Atopic Dermatitis in Elderly Patients: Discussing the Safety of Lebrikizumab in an 86-Year-Old Patient.

0 SAR
Checkout

Overview

In this video, Dr. Naiem T. Issa reviews the established safety profile of Ebglyss®
(lebrikizumab), including key safety considerations, common adverse events, and its use
without routine lab monitoring or dose adjustments. He also presents a real-world case of
an 86-year-old patient with severe atopic dermatitis, demonstrating rapid improvements in
BSA and itch severity within just 2 weeks of treatment, highlighting the safety and fast
efficacy of lebrikizumab in elderly patients.


This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

  • ● Review the established safety profile of lebrikizumab in adults and adolescents.
    ● Highlight key safety considerations, including no routine lab monitoring and no dose adjustments by age or weight.
    ● Summarize common adverse events reported in clinical trials.
    ● Demonstrate the rapid efficacy and safety of lebrikizumab through a real-world case in an elderly patient with comorbidities.

     

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    PP-LK-SA-0267


Related Classes